• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用计算机筛选和等温滴定量热法发现MDM2小分子抑制剂

Application of In Silico Filtering and Isothermal Titration Calorimetry for the Discovery of Small Molecule Inhibitors of MDM2.

作者信息

Alali Hen, Bloch Itai, Rapaport Irena, Rodrigues Luisa, Sher Inbal, Ansbacher Tamar, Gal Maayan

机构信息

Department of Oral Biology, Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Migal-Galilee Research Institute, Tel-Hai Academic College, Upper Galilee 12210, Israel.

出版信息

Pharmaceuticals (Basel). 2022 Jun 16;15(6):752. doi: 10.3390/ph15060752.

DOI:10.3390/ph15060752
PMID:35745671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9230431/
Abstract

The initial discovery phase of protein modulators, which consists of filtering molecular libraries and in vitro direct binding validation, is central in drug discovery. Thus, virtual screening of large molecular libraries, together with the evaluation of binding affinity by isothermal calorimetry, generates an efficient experimental setup. Herein, we applied virtual screening for discovering small molecule inhibitors of MDM2, a major negative regulator of the tumor suppressor p53, and thus a promising therapeutic target. A library of 20 million small molecules was screened against an averaged model derived from multiple structural conformations of MDM2 based on published structures. Selected molecules originating from the computational filtering were tested in vitro for their direct binding to MDM2 via isothermal titration calorimetry. Three new molecules, representing distinct chemical scaffolds, showed binding to MDM2. These were further evaluated by exploring structure-similar chemical analogues. Two scaffolds were further evaluated by de novo synthesis of molecules derived from the initial molecules that bound MDM2, one with a central oxoazetidine acetamide and one with benzene sulfonamide. Several molecules derived from these scaffolds increased wild-type p53 activity in MCF7 cancer cells. These set a basis for further chemical optimization and the development of new chemical entities as anticancer drugs.

摘要

蛋白质调节剂的初始发现阶段包括筛选分子文库和进行体外直接结合验证,这在药物发现中至关重要。因此,对大分子文库进行虚拟筛选,并通过等温滴定量热法评估结合亲和力,构成了一个高效的实验方案。在此,我们应用虚拟筛选来发现MDM2的小分子抑制剂,MDM2是肿瘤抑制因子p53的主要负调控因子,因此是一个有前景的治疗靶点。针对基于已发表结构的MDM2多种结构构象推导的平均模型,对一个包含2000万个小分子的文库进行了筛选。对计算筛选出的分子进行体外测试,通过等温滴定量热法检测它们与MDM2的直接结合情况。三个代表不同化学骨架的新分子显示出与MDM2结合。通过探索结构相似的化学类似物对它们进行了进一步评估。通过从头合成源自与MDM2结合的初始分子的分子,对其中两个骨架进行了进一步评估,一个含有中心氧杂氮杂环丁烷乙酰胺,另一个含有苯磺酰胺。从这些骨架衍生出的几个分子在MCF7癌细胞中提高了野生型p53的活性。这些为进一步的化学优化以及开发作为抗癌药物的新化学实体奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/2b2dd3d60660/pharmaceuticals-15-00752-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/302b486dce10/pharmaceuticals-15-00752-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/8ab9b7b2faf8/pharmaceuticals-15-00752-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/58a1531cbc85/pharmaceuticals-15-00752-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/250f8187e9fd/pharmaceuticals-15-00752-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/3d1200a01ed4/pharmaceuticals-15-00752-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/2b2dd3d60660/pharmaceuticals-15-00752-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/302b486dce10/pharmaceuticals-15-00752-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/8ab9b7b2faf8/pharmaceuticals-15-00752-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/58a1531cbc85/pharmaceuticals-15-00752-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/250f8187e9fd/pharmaceuticals-15-00752-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/3d1200a01ed4/pharmaceuticals-15-00752-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8307/9230431/2b2dd3d60660/pharmaceuticals-15-00752-g006.jpg

相似文献

1
Application of In Silico Filtering and Isothermal Titration Calorimetry for the Discovery of Small Molecule Inhibitors of MDM2.利用计算机筛选和等温滴定量热法发现MDM2小分子抑制剂
Pharmaceuticals (Basel). 2022 Jun 16;15(6):752. doi: 10.3390/ph15060752.
2
Efficient Isothermal Titration Calorimetry Technique Identifies Direct Interaction of Small Molecule Inhibitors with the Target Protein.高效等温滴定量热法技术鉴定小分子抑制剂与靶蛋白的直接相互作用。
Comb Chem High Throughput Screen. 2016;19(1):4-13. doi: 10.2174/1386207319666151203001529.
3
An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.一种综合的计算机筛选策略,用于识别有希望破坏 p53-MDM2 相互作用的化合物。
Comput Biol Chem. 2019 Dec;83:107105. doi: 10.1016/j.compbiolchem.2019.107105. Epub 2019 Aug 16.
4
Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.抗精神病药物氟司必林作为潜在的p53-MDM2抑制剂的鉴定:一项计算与实验相结合的研究。
J Comput Aided Mol Des. 2015 Feb;29(2):155-63. doi: 10.1007/s10822-014-9811-6. Epub 2014 Nov 7.
5
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.p53-Mdm2 相互作用抑制剂作为新型非遗传毒性抗癌药物。
Curr Cancer Drug Targets. 2018;18(8):749-772. doi: 10.2174/1568009617666170623111953.
6
An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.适配质量在筛选 MDM2/p53 蛋白-蛋白相互作用抑制剂中的应用。
Molecules. 2018 Dec 1;23(12):3174. doi: 10.3390/molecules23123174.
7
Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.提出新型 MDM2 抑制剂:结合物理驱动的高通量虚拟筛选和体外研究。
Chem Biol Drug Des. 2020 Jul;96(1):684-700. doi: 10.1111/cbdd.13694.
8
Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction.整合虚拟筛选和分子动力学模拟揭示了 p53-MDM2 相互作用有前景的药物候选物。
J Mol Model. 2022 May 10;28(6):142. doi: 10.1007/s00894-022-05131-w.
9
Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.基于集成的虚拟筛选揭示了针对 p53-MDM2/MDMX 相互作用的双抑制剂。
J Mol Graph Model. 2010 Feb 26;28(6):555-68. doi: 10.1016/j.jmgm.2009.12.003. Epub 2009 Dec 14.
10
Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.通过基于结构的虚拟筛选策略鉴定MDM2-p53相互作用的高亲和力非肽小分子抑制剂。
Asian Pac J Cancer Prev. 2015;16(9):3759-65. doi: 10.7314/apjcp.2015.16.9.3759.

本文引用的文献

1
Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.癌症治疗中的治疗机会:靶向p53-MDM2/MDMX相互作用
Am J Cancer Res. 2021 Dec 15;11(12):5762-5781. eCollection 2021.
2
Editorial: Protein-Protein Interactions: Drug Discovery for the Future.社论:蛋白质-蛋白质相互作用:未来的药物发现
Front Chem. 2021 Nov 29;9:811190. doi: 10.3389/fchem.2021.811190. eCollection 2021.
3
Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs.设计蛋白质-蛋白质相互作用靶向药物的当前挑战与机遇
Adv Appl Bioinform Chem. 2020 Nov 12;13:11-25. doi: 10.2147/AABC.S235542. eCollection 2020.
4
Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.近期的 p53-MDM2 蛋白-蛋白相互作用小分子抑制剂。
Molecules. 2020 Mar 7;25(5):1211. doi: 10.3390/molecules25051211.
5
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).MDM2-p53 相互作用抑制剂:最新专利技术回顾(2010 年至今)。
Recent Pat Anticancer Drug Discov. 2019;14(4):324-369. doi: 10.2174/1574892814666191022163540.
6
A Small Molecule Inhibitor of Bruton's Tyrosine Kinase Involved in B-Cell Signaling.一种参与B细胞信号传导的布鲁顿酪氨酸激酶小分子抑制剂。
ACS Omega. 2017 Aug 9;2(8):4398-4410. doi: 10.1021/acsomega.7b00576. eCollection 2017 Aug 31.
7
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.靶向 p53-MDM2/MDMX 的潜在小分子药物治疗癌症的过去、现在和未来。
Eur J Med Chem. 2019 Aug 15;176:92-104. doi: 10.1016/j.ejmech.2019.05.018. Epub 2019 May 8.
8
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).MDM2/X 靶向治疗的治疗性专利概述(2014-2018 年)。
Expert Opin Ther Pat. 2019 Mar;29(3):151-170. doi: 10.1080/13543776.2019.1582645. Epub 2019 Mar 1.
9
Repeatability, precision, and accuracy of the enthalpies and Gibbs energies of a protein-ligand binding reaction measured by isothermal titration calorimetry.通过等温滴定量热法测量的蛋白质-配体结合反应的焓和吉布斯自由能的可重复性、精密度和准确度。
Eur Biophys J. 2019 Mar;48(2):139-152. doi: 10.1007/s00249-018-1341-z. Epub 2018 Dec 8.
10
Tumor suppressor p53 and metabolism.肿瘤抑制因子 p53 与代谢。
J Mol Cell Biol. 2019 Apr 1;11(4):284-292. doi: 10.1093/jmcb/mjy070.